Merck (MRK)
$90.49
1.11 (1.22%)
MRK Stock Quote Delayed 30 Minutes
Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$91.43
Market Cap
226.10B
PE Ratio
13.43
EPS
6.7363
Volume (Avg. Vol.)
13.20M
Day's Range
$88.86 - $91.37
52-Week Range
$81.04 - $132.70
Dividend & Yield
$3.12 (3.45%)
MRK Stock Predictions, Articles, and Merck News
4 Drug Stocks Getting Smashed
Drug stocks are falling on fears of President Trump's next move on drug prices. Here's a look at the charts.
Dow Jones Today: Averting Catastrophe, but Nothing to Brag About
As has been noted in this space, market participants are pricing in the following Fed facts: no interest rate cut this month and no cuts totaling 50 basis points this year. Hope burns eternal for a rate reduction of 25 basis points, but Powell's two-day testimony and the June meeting minutes could indicate otherwise.
Two Healthcare Stocks in the XLV Fund Stand Out
MRK stock and ABBV stock are promising healthcare stocks to invest in from the XLV fund. MRK is 6% of holdings and AbbVie makes up 3.5%.
Profit from Earnings Volatility With This Biotech Stocks Pairs Trade
Play a friendly and widening price spread in biotech stocks with a well-place purchase in Merck and an equally smart short in AbbVie.
Why Investors Should Buy the Dip in MRK Stock
The fall in MRK, and other drug stocks, was based on fear of a drug price backlash that has not yet materialized.
Why Is Bristol-Myers Near 52-Week Lows?
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock's acquisition of Celgene isn't the only reason.
Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
10 Dow Jones Stocks Holding the Blue Chip Index Back
Pfizer, Walgreens and Merck are just three of the Dow Jones stocks that have kept the index from doing as well as other market indices have this year.
Thursday’s Vital Data: Aurora Cannabis, Roku and Merck
Options trading was buzzing in Aurora Cannabis, Roku and Merck on Wednesday. Here are the metrics that matter moving forward.
5 Stock Charts Ripe for a Breakout
When looking for stocks to buy, one method is to study the charts and see which stocks look poised for a breakout. Here are 5.
Merck News: MRK Stock Moves Higher on Q4 Earnings Beat
Merck news about the pharmaceutical company's performance during the fourth quarter of the year has MRK stock up on Friday.
3 Big Stock Charts for Monday: Pfizer, MGM Resorts and Incyte
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
3 Big Stock Charts for Friday: Merck, Broadcom and Advanced Micro Devices
Three stocks -- AMD, MRK and AVGO -- are going to end the week with their charts in pivotal positions. Here's what to watch.
All Signals Are Positive for Buying Abbott Laboratories
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
3 Big Stock Charts for Thursday: Fiserv, Pfizer and PNC Financial Services Group
Stock charts of FISV, PFE and PNC are run through the technical trading wringer, and come out as your top prospects.
